Literature DB >> 12112099

Sickle cell disease: the neurological complications.

Mara Prengler1, Steven G Pavlakis, Isak Prohovnik, Robert J Adams.   

Abstract

The genetic cause of sickle cell disease has been known for decades, yet the reasons for its clinical variability are not fully understood. The neurological complications result from one point mutation that causes vasculopathy of both large and small vessels. Anemia and the resultant cerebral hyperemia produce conditions of hemodynamic insufficiency. Sickled cells adhere to the endothelium, contributing to a cascade of activated inflammatory cells and clotting factors, which result in a nidus for thrombus formation. Because the cerebrovascular reserve becomes exhausted, the capacity for compensatory cerebral mechanisms is severely limited. There is evidence of small-vessel sludging, and a relative deficiency of nitric oxide in these vessels further reduces compensatory vasodilatation. Both clinical strokes and silent infarcts occur, affecting motor and cognitive function. New data suggest that, in addition to sickle cell disease, other factors, both environmental (eg, hypoxia and inflammation) and genetic (eg, mutations resulting in thrombogenesis), may contribute to a patient's stroke risk. The stroke risk is polygenic, and sickle cell disease can be considered a model for all cerebrovascular disease. This complex disease underscores the potential intellectual and practical distance between the determination of molecular genetics and effective clinical application and therapeutics.

Entities:  

Mesh:

Year:  2002        PMID: 12112099     DOI: 10.1002/ana.10192

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  37 in total

Review 1.  Imaging in childhood arterial ischaemic stroke.

Authors:  Brynmor P Jones; Vijya Ganesan; Dawn E Saunders; W Kling Chong
Journal:  Neuroradiology       Date:  2010-05-06       Impact factor: 2.804

2.  Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Authors:  Gregory J Kato; Matthew Hsieh; Roberto Machado; James Taylor; Jane Little; John A Butman; Tanya Lehky; John Tisdale; Mark T Gladwin
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

Review 3.  Stroke in Black Americans.

Authors:  Sean Ruland; Philip B Gorelick
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

4.  Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

Review 5.  Single gene disorders causing ischaemic stroke.

Authors:  Saif S M Razvi; Ian Bone
Journal:  J Neurol       Date:  2006-06       Impact factor: 4.849

Review 6.  Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.

Authors:  Junaid Ansari; Youmna E Moufarrej; Rafal Pawlinski; Felicity N E Gavins
Journal:  Expert Rev Hematol       Date:  2017-12-05       Impact factor: 2.929

7.  Determining Adherence to Quality Indicators in Sickle Cell Anemia Using Multiple Data Sources.

Authors:  Cindy E Neunert; Robert W Gibson; Peter A Lane; Pragya Verma-Bhatnagar; Vaughn Barry; Mei Zhou; Angela Snyder
Journal:  Am J Prev Med       Date:  2016-07       Impact factor: 5.043

Review 8.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

9.  Genetic endothelial systems biology of sickle stroke risk.

Authors:  Liming Chang Milbauer; Peng Wei; Judy Enenstein; Aixiang Jiang; Cheryl A Hillery; J Paul Scott; Stephen C Nelson; Vidya Bodempudi; James N Topper; Ruey-Bing Yang; Betsy Hirsch; Wei Pan; Robert P Hebbel
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

Review 10.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.